XTX 301
Alternative Names: XTX-301Latest Information Update: 03 Apr 2024
At a glance
- Originator Xilio Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Mar 2024 XTX 301 licensed to Gilead Sciences
- 08 Jan 2024 Preliminary adverse event data from a phase I trial in Solid tumours released by Xilio Therapeutics
- 14 Apr 2023 Interim safety and pharmacodynamic data from a preclinical studies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)